Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Alvine Pharmaceuticals (Asstes)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

The assets include ALV003, a mixture of two gluten-specific recombinant proteases engineered to digest gluten and to treat patients with celiac disease. Latiglutenase (formerly known as ALV003 and renamed IMGX-003) is an orally administered mixture of two recombinant gluten-specific proteases including glutamine-specific cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP) to treat celiac disease.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Acquirer
ImmunogenX
Primary Office
  • Shoreway Road
  • Suite B
  • San Carlos, CA
  • United States

Alvine Pharmaceuticals (Asstes) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Alvine Pharmaceuticals (Asstes)‘s full profile, request access.

Request full access to PitchBook